Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAd3-Sudan Ebolavirus Vaccine in Healthy Adults
NCT06036602Phase 2Completed
- Sponsor
- Sabin Vaccine Institute
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of cAd3-EBO S in Sudan virus disease (SVD), sponsored by Sabin Vaccine Institute. Started Jul 2024; status: completed.
02
Drugs
cAd3-EBO S
03
Conditions
Sudan virus disease (SVD)
Beyond the preview
Go deeper on NCT06036602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06036602.